Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?

Clinical Therapeutics

Volumn 35, Issue 12, 2013, Pages 2028-2035

  Tanaka, Yoshiya ^a   Hirata, Shintaro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Biologic; Discontinuation; Remission; Rheumatoid arthritis; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

CLINICAL DISEASE ACTIVITY INDEX; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; EROSION; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SAFETY; REMISSION; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEROCONVERSION; SYNOVITIS; TREATMENT DURATION; TREATMENT RESPONSE;

BIOLOGIC; DISCONTINUATION; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890312619     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.10.008     Document Type: Review

References (27)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
2. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
3. Redlich K., Smolen J.S. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discovery 2012, 11:234-250.
4. Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012, 24:319-326.
5. Tanaka Y. Next stage of RA treatment: TNF-inhibitor-free remission will be a possible treatment goal?. Ann Rheum Dis 2013, 72:ii124-ii127.
6. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
7. van den Broek M., Klarenbeek N.B., Dirven L., et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011, 70:1389-1394.
8. Klarenbeek N.B., van der Kooij S.M., Güler-Yüksel M., et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011, 70:315-319.
9. Bejarano V., Conaghan P.G., Quinn M.A., et al. Benefits 8 years after a remission induction regimen with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:1971-1974.
10. Tanaka Y., Takeuchi T., Mimori T., et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (Remission Induction by Remicade in RA) study. Ann Rheum Dis 2010, 69:1286-1291.
11. Nawata M., Saito K., Nakayamada S., Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008, 18:460-464.
12. van der Kooij S.M., le Cessie S., Goekoop-Ruiterman Y.P., et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009, 68:1153-1158.
13. van der Bijl A.E., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007, 56:2129-2134.
14. Quinn M.A., Conaghan P.G., O'Connor P.J., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27-35.
15. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized controlled trial. Arthritis Rheum 2005, 52:3381-3390.
16. Smolen J.S., Nash P., Durez P., et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 2013, 381:918-929.
17. Kavanaugh A., Fleischmann R.M., Emery P., et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013, 72:64-71.
18. Kavanaugh A., Emery P., Fleischman R., et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial [abstract]. Arthritis Rheum 2011, 63:S665.
19. Detert J., Bastian H., Listing J., et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013, 72:844-850.
20. Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining DAS28 (ESR) remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. In press.
21. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthiritis: 1-year outcome of the HONOR study. Ann Rheum Dis. In press.
22. Smolen J.S., Emery P., Ferraccioli G., et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study. Ann Rheum Dis 2012, 71(Suppl 3):361.
23. Kaymakcalan Z., Sakorafas P., Bose S., et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009, 131:308-316.
24. Arora T., Padaki R., Liu L., et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009, 45:124-131.
25. Mitoma H., Horiuchi T., Tsukamoto H., et al. Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNF-expressing cells: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum 2008, 58:1248-1257.
26. Tanaka Y, Takeuchi T, Mimori T, et al. RRR study investigators. The possibility and predictive factors of maintaining low disease activity and joint structure after discontinuation of infliximab in RA patients: results from 3-year experience of RRR study. Ann Rheum Dis. 2013;72(Suppl 3):443.
27. van den Hout W.B., Goekoop-Ruiterman Y.P., Allaart C.F., et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2009, 61:291-299.